Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Safety of Abrupt Discontinuation of Fluoxetine: A Randomized, Placebo-Controlled Study

Abstract

Selective serotonin reuptake inhibitors may be associated with new adverse events after abrupt discontinuation. Hypothesizing that the long half-life of fluoxetine would be protective, this study analyzed the effects of abrupt fluoxetine discontinuation during a randomized, double-blind, placebo-controlled study of depression maintenance treatment. After 12 weeks of fluoxetine treatment (20 mg/day), 395 responders were abruptly randomized to placebo (N = 96) or to continued fluoxetine (N = 299). Patients were seen at weeks 1, 2, 4, and 6 after randomization. Reports of new or worsened adverse events were similar for both groups at each visit after randomization. Patient discontinuations related to adverse events were also similar in both groups. Mild, self-limited lightheadedness or dizziness occurred in a small percentage of patients who discontinued fluoxetine treatment but was of little clinical significance. No cluster of symptoms suggestive of a discontinuation syndrome was observed. Abrupt discontinuation of fluoxetine treatment was well tolerated and did not seem to be associated with significant clinical risk. Fluoxetine may offer a potential safety advantage over shorter-acting agents with respect to treatment interruption and/or discontinuation and may be a better choice for those patients who are likely to miss doses because of travel or forgetfulness.

Overview

Integrity signals

Registry

Crossref · 10.1097/00004714-199806000-00003

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 8 references

Research works printed but not linked: 5

  1. Debattista, 1995, Am J Psychiatry, 152, 1235
  2. Kouie, 1994, Am J Psychiatry, 151, 450
  3. Einbinder, 1995, Am J Psychiatry, 152, 1235
  4. Stoukides, 1991, Am J Psychiatry, 148, 1263
  5. Kasantikul, 1995, J Med Assoc Thai, 78, 53

Cited by

See all 85

Metadata

Authors
Zajecka, J., Fawcett, J., Amsterdam, J., Quitkin, F., Reimherr, F., Rosenbaum, J., Michelson, D., & Beasley, C.
Affiliations
  • Rush University Medical Center (US)
  • Rush University (US)
  • University of Pennsylvania (US)
  • Columbia University (US)
  • Harvard University (US)
  • Eli Lilly (United States) (US)
Venue
Journal of Clinical Psychopharmacology
Published
1998-06
Volume
18
Issue
3
Pages
193-197
ISSN
0271-0749 (ISSN-L)
OpenAlex
W2015255754
Cited by
85
References
8
Citations by year
2026: 1 · 2025: 4 · 2024: 7 · 2023: 3 · 2022: 4 · 2021: 6 · 2019: 8 · 2018: 3 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 1 · 2013: 2 · 2012: 2
FWCI
4.40
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords
fluoxetine, selective serotonin reuptake inhibitors, discontinuation syndrome, adverse events, drug safety, dizziness
MeSH terms
Adult, Depressive Disorder, Dizziness, Double-Blind Method, Female, Fluoxetine, Humans, Male, Middle Aged, Prospective Studies, Substance Withdrawal Syndrome, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety of Abrupt Discontinuation of Fluoxetine: A Randomized, Placebo-Controlled Study. https://app.cochat.ai/papers/10.1097/00004714-199806000-00003
The paper
Zajecka, J., Fawcett, J., Amsterdam, J., Quitkin, F., Reimherr, F., Rosenbaum, J., Michelson, D., & Beasley, C. (1998). Safety of Abrupt Discontinuation of Fluoxetine: A Randomized, Placebo-Controlled Study. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199806000-00003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.